Qiagen stock slips despite Q2 earnings beat and stable guidance
Qiagen's stock declined on August 21, 2026, despite the company reporting a beat on Q2 2026 revenue and adjusted EPS, and maintaining its full-year guidance. The market's cautious reaction saw the stock among the biggest decliners on Germany's DAX index, though its US-listed shares had a slight gain the previous day. Analysts generally rate the stock as "accumulate," with an average price target implying a modest upside.
Qiagen stock advances after topping DAX winners with fresh gain
Qiagen N.V. stock has shown renewed strength, leading DAX gainers with a 2.04% rise on August 19, 2026, and a 5.05% gain over five trading days for its US-listed shares, reaching a market capitalization of $9.189 billion. This comes as investors assess the impact of a recent cash-and-stock merger and analyze the company's valuation against its February 2026 market cap of $10.38 billion. The company, known for its diagnostic and sample preparation products, is navigating market sentiment shaped by both its corporate actions and sector trends.
PTA-AFR: QIAGEN N.V.: Pre-announcement of a financial report according to articles 114 - 117 WpHG
QIAGEN N.V. has pre-announced the disclosure of its half-year report for 2026, covering the period from January 1, 2026, to June 30, 2026. The report will be published online on August 21, 2026, on the company's corporate website. This announcement is made in accordance with articles 114 - 117 WpHG.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
Pomerantz LLP is investigating potential securities fraud claims against Qiagen N.V. (NYSE: QGEN) on behalf of its investors. This investigation follows a significant drop in Qiagen's stock price after the company announced lower-than-expected preliminary first-quarter 2026 results, including a decline in net sales and QuantiFERON product sales. Investors who suffered losses are encouraged to contact the law firm to learn about joining a potential class action.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a voting rights announcement as required by Article 40, Section 1 of the WpHG, based on a notification received from the AFM. The announcement details BlackRock, Inc.'s holdings in QIAGEN N.V. as of August 13, 2026, including their direct and indirect capital interests and voting rights, which total 11.62% and 13.01% respectively.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, following a notification from the AFM. The announcement details Goldman Sachs Group Inc.'s voting rights in QIAGEN, outlining both real and potential holdings across various share types and methods of disposal. The total capital interest and voting rights held by Goldman Sachs Group Inc. are reported as 3.05%.
One Fin Capital Management LP's Qiagen NV(QGEN) Holding History
This article details One Fin Capital Management LP's holdings in Qiagen NV (QGEN) as of Q2 2026. The firm holds 400,000 shares valued at $15.64 million, representing 5.05% of its portfolio and an estimated gain of 13.82% on the investment. The initial purchase occurred in 2026Q2 at an average price of $37.18 per share.
Qiagen stock holds steady after Q2 2026 beat and guidance reaffirmation
Qiagen N.V. stock is holding steady in the low-$40s after reporting a modest earnings beat for Q2 2026 and reaffirming its full-year guidance. The company's performance was bolstered by stable growth and ongoing innovation, particularly with the recent regulatory clearance of its QIAstat-Dx sepsis panel, which strengthens its position in molecular diagnostics. Analysts largely rate the stock as "Hold," with the current price close to the average target, suggesting a balanced risk-reward profile, while institutional interest remains consistent.
QIAGEN NV Revenue Breakdown – TRADEGATE:QIA
QIAGEN NV (TRADEGATE:QIA) reported a total revenue of €1.78 billion last year. The Diagnostic Solutions segment was the top performer, generating €683.76 million, although this was a decrease from the previous year's €723.42 million. The United States was the largest geographical contributor, accounting for €850.10 million in revenue.
Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a notification regarding a voting rights announcement, as informed by the AFM. Wellington Management Group LLP notified the AFM on August 14, 2026, about a transaction dated August 12, 2026, where their voting rights in QIAGEN N.V. are 4.96%, totaling 10,253,341 shares. QIAGEN N.V. emphasizes that it is not responsible for the accuracy of this notification, which is sourced from the AFM's public register.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
This article announces that QIAGEN N.V. has received a notification from the AFM (the Netherlands Authority For the Financial Markets) regarding a voting rights announcement. Wellington Management Group LLP reported a transaction on August 12, 2026, indicating they hold 4.96% of the voting rights in QIAGEN N.V. QIAGEN N.V. clarifies that it is not responsible for the accuracy of this notification, which is based on information from the AFM's register.
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR
This article announces a manager's transaction at QIAGEN N.V. involving Eva Pisa, a member of the administrative or supervisory body. The transaction is a retroactive adjustment for a February 2026 net share settlement, withholding an additional 544 shares to cover related taxes, and is linked to the exercise of share option programs. The transaction date was August 11, 2026, and it occurred outside a trading venue.
Qiagen N.V. : DZ Bank reiterates its Buy rating
DZ Bank has reiterated its "Buy" rating for Qiagen N.V. Analyst Sven Kürten confirmed his positive recommendation for the biotechnology and medical research company. Qiagen N.V. is a global leader in providing chemical products for DNA and RNA manipulation.
Goldman Sachs Discloses 2.63% Voting Interest in Qiagen via AFM Filing
Goldman Sachs Group Inc. has disclosed a 2.63% voting interest in Qiagen N.V., a Netherlands-based life sciences company, through a filing with the Dutch Authority for the Financial Markets. This stake is composed of both indirect real holdings and potential positions via various derivative instruments. The announcement highlights ongoing institutional activity in Qiagen shares and provides transparency for investors regarding significant equity exposures.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, following a notification from the AFM on August 7, 2026. The announcement details Goldman Sachs Group Inc.'s holdings in QIAGEN N.V., including various types of shares and financial instruments, and specifies both real and potential voting rights and capital interests. Goldman Sachs' total capital interest and voting rights stand at 2.63%.
Qiagen N.V. : Deutsche Bank remains its Buy rating
Deutsche Bank has reiterated its "Buy" rating on Qiagen N.V. stock, with analyst Jan Koch advising clients to purchase the shares. This follows earlier news from August 6th where Jefferies also reiterated its "Buy" rating for Qiagen N.V. The company recently reported strong Q2 2026 results, with adjusted earnings and revenue rising and exceeding analyst expectations, though guidance remains unchanged.
63,219 Shares in Qiagen N.V. $QGEN Bought by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company recently acquired 63,219 shares of Qiagen N.V. (NYSE:QGEN) worth approximately $2.52 million. This purchase is part of broader institutional investment, with various firms like Boston Partners, Norges Bank, and Price T Rowe Associates also holding significant stakes, bringing total institutional ownership to 70%. Despite this, analysts maintain a "Hold" rating for QGEN with an average price target of $43.34, even though the company surpassed recent quarterly earnings and revenue expectations and increased its annual dividend.
Qiagen N.V. (NYSE: QGEN) Q2 2026 profit, $496.7M synthetic buyback and cash flows
QIAGEN N.V. (NYSE: QGEN) reported Q2 2026 net sales of $535.04 million and net income of $103.401 million, with diluted EPS of $0.50. The company executed a $496.7 million synthetic share repurchase in January 2026, reducing outstanding shares by 5.0%, and approved a $0.35 per share cash dividend for 2026. Operating cash flows for the first half of 2026 were $301.319 million, consistent with the prior year.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a voting rights announcement per Article 40, Section 1 of the WpHG, following a notification from the AFM. The notification details that The Vanguard Group holds 2.92% of QIAGEN N.V.'s capital and voting rights as of July 30, 2026, corresponding to 6,045,368 ordinary shares. QIAGEN N.V. clarifies that it is not responsible for the accuracy of the notification, which was sourced from the AFM's public register.
Qiagen N.V. Stock 12‑Month Price Target Raised to $44.52, Implies 7% Upside
Qiagen N.V.'s average price target has been increased from $43.87 to $44.52 by 17 analysts, suggesting a 7% potential upside based on its closing price. The consensus rating remains a "Buy" from 22 covering analysts. Investors can explore more price target data and analyst recommendations on TradingView.
Qiagen NV | 6-K: Report of foreign private issuer (related to financial reporting)
This article is a 6-K filing by Qiagen NV, which is a report for a foreign private issuer. These reports are typically related to financial reporting and other significant company updates that are required by regulatory bodies.
PTA-CMS: QIAGEN N.V.: Release of a capital market information
QIAGEN N.V. has filed its Form 6-K Report of Foreign Private Issuer for the quarterly period ended June 30, 2026, with the United States Securities and Exchange Commission (SEC). The document is now accessible on QIAGEN's website. This release provides important capital market information for investors.
Quantinno Capital Management LP Has $5.30 Million Stock Holdings in Qiagen N.V. $QGEN
Quantinno Capital Management LP significantly reduced its stake in Qiagen N.V. by 40.6% in the first quarter, now holding 132,392 shares valued at approximately $5.3 million. Despite this, Qiagen's recent quarterly earnings exceeded expectations, with EPS of $0.62 and revenue of $535 million, and the company reaffirmed its 2026 EPS outlook of $2.43. However, near-term revenue guidance for the third quarter and full year fell below analyst expectations, leading to a consensus "Hold" rating with an average price target of $42.43.
QIAGEN N.V. (NYSE: QGEN) tops Q2 EPS outlook and reaffirms 2026 targets
QIAGEN N.V. exceeded its Q2 2026 EPS outlook with adjusted diluted EPS of $0.62, against an outlook of at least $0.60 CER, and reaffirmed its full-year 2026 guidance for net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 CER. Despite a challenging operating environment and cautious capital spending, the company maintained high profitability and saw solid growth in its key pillars, particularly Sample technologies. QIAGEN also detailed advancements in AI-powered tools, automated workflows for TB detection, and expansion of its QIAcuity and QIAstat-Dx portfolios.
A Quick Look at Today's Ratings for Qiagen NV(QGEN.US), With a Forecast Between $45.5 to $46.09
This article provides a quick look at today's analyst ratings for Qiagen NV (QGEN.US), forecasting a target price between $45.50 and $46.09. It highlights the general sentiment and price targets from various financial institutions.
QIAGEN N.V. (NYSE: QGEN) sets $0.35 dividend and $200M buyback cap
QIAGEN N.V. (NYSE: QGEN) announced it will convene its 2026 Annual General Meeting on June 24, 2026. Shareholders will vote on a proposed cash dividend of $0.35 per ordinary share, totaling approximately $72 million, payable July 14, 2026. Additionally, the agenda includes authorizing a synthetic share repurchase of up to $200 million via capital repayment, alongside other corporate governance and remuneration policy updates.
Bank of America Corp DE Sells 418,992 Shares of Qiagen N.V. $QGEN
Bank of America Corp DE reduced its stake in Qiagen N.V. (NYSE:QGEN) by 11.4% in the first quarter, selling 418,992 shares and retaining 3.25 million shares valued at approximately $130 million. Qiagen exceeded second-quarter earnings and revenue expectations, reporting $0.62 adjusted EPS and $535 million in revenue, but provided third-quarter and full-year revenue guidance below analyst estimates. Analyst sentiment on QGEN is mixed, with a consensus "Hold" rating and an average price target of $42.43.
Qiagen N.V. Stock 12‑Month Price Target Raised to $43.5, Implies 4% Upside
Analysts have raised the 12-month average price target for Qiagen N.V. (QGEN) stock from $43.12 to $43.5, with individual forecasts ranging from $37.55 to $49 per share. This updated target suggests a potential upside of approximately 4% based on the August 5th closing price. The consensus rating from 22 analysts remains "Buy," with 10 recommending Buy and 12 recommending Hold.
Qiagen N.V. : Jefferies reiterates its Buy rating
Jefferies has reiterated its "Buy" rating for Qiagen N.V., reflecting a positive outlook on the stock. This comes as Qiagen's Q2 earnings exceeded expectations, though the company has maintained its guidance, similar to its peers. The article also provides a brief company profile, financial data, and analyst consensus, indicating a generally positive sentiment towards Qiagen.
Qiagen NV (0RLT) Q4 2024 Earnings Report - Results, Call & Slides
Qiagen NV (0RLT) reported its Q4 2024 earnings, with an actual EPS of €0.56 matching the consensus but missing by less than €0.01 against expectations. The company's revenue for Q4 2024 was €452.34M, slightly beating the expected €452.21M. Qiagen also provided details for its upcoming earnings, with the next estimated report for Q3 2026 on November 10, 2026.
QIAGEN NV : Deutsche Bank maintains a Buy rating
Deutsche Bank has reiterated its Buy rating for QIAGEN NV, with analyst Jan Koch maintaining a positive outlook on the stock. This comes amidst recent news that Jefferies also reiterated a Buy rating for QIAGEN and that the company's Q2 earnings were ahead of expectations, though guidance remains unchanged. QIAGEN N.V. is a global leader in DNA and RNA isolation, purification, and manipulation products.
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
Qiagen (QGEN) exceeded Q2 earnings and revenue estimates, reporting $0.62 per share against a $0.60 consensus and revenues of $535.04 million, surpassing the $527.91 million estimate. Despite the beat, the company's shares have underperformed the S&P 500 year-to-date, and its Zacks Rank of #4 (Sell) suggests potential underperformance in the near future.
Janus Henderson Group PLC Makes New Investment in Qiagen N.V. $QGEN
Janus Henderson Group PLC has made a new investment in Qiagen N.V., purchasing 366,661 shares valued at approximately $14.6 million, giving it a 0.18% stake. Other institutional investors have also adjusted their holdings, with institutional ownership of Qiagen reaching 70%. Analyst sentiment for Qiagen is mixed, with a consensus "Hold" rating and a $43.34 average price target, while the company reported quarterly EPS matching estimates and increased its annual dividend.
QIAGEN NV Revenue Breakdown – BIVA:QIA/N
QIAGEN NV (BIVA:QIA/N) generated 37.68 billion MXN in revenue last year. Its top-performing segment was Diagnostic Solutions, contributing 14.48 billion MXN. The United States was the largest regional contributor, accounting for 18.00 billion MXN of the total revenue.
Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM. T. Rowe Price Group, Inc. reported a transaction on July 29, 2026, showing a capital interest and voting rights distribution of 4.97% in QIAGEN N.V. The company emphasizes it is not responsible for the accuracy of this third-party notification.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a notification regarding a voting rights announcement from the AFM (the Netherlands Authority For the Financial Markets). The notification, dated August 1, 2026, details changes in share and voting rights distributions for QIAGEN N.V. related to transactions made by Barclays Plc on July 28, 2026.
Segall Bryant & Hamill LLC Lowers Holdings in Qiagen N.V. $QGEN
Segall Bryant & Hamill LLC reduced its stake in Qiagen N.V. by 24.5% in the first quarter, selling 36,110 shares but still retaining 111,177 shares worth approximately $4.45 million. Despite this reduction, other institutional investors like Groupe la Francaise, Janus Henderson Group PLC, Amundi, EverSource Wealth Advisors LLC, and Royal Bank of Canada increased their holdings in QGEN. Qiagen reported quarterly EPS matching expectations but revenue slightly below estimates, increased its annual dividend, and maintains an average "Hold" rating from analysts with a target price of $43.34.
Qiagen NV expected to post earnings of 60 cents a share - Earnings Preview
Qiagen NV is projected to report earnings of 60 cents per share. This information comes from a Refinitiv earnings preview. The full article content is available on TradingView, which aggregates news from various sources including Reuters.
Qiagen NV (QGEN.BRN) Q4 2024 Earnings Report - Results, Call & Slides
Qiagen NV (QGEN.BRN) reported its Q4 2024 earnings, missing the consensus EPS estimate by -CHF0.01 with an actual EPS of CHF0.52. However, the company beat revenue expectations, reporting CHF424.78M against an expected CHF424.66M, marking a 2.36% year-over-year revenue growth. The earnings call and slide deck for Q4 2024 are available, and the next earnings date is estimated for August 5, 2026.
Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM. The notification details a transaction date of July 27, 2026, involving Goldman Sachs Group Inc., and outlines the distribution of shares, voting rights, and capital interests held by Goldman Sachs indirectly through various entities. The total indirect capital interest and voting rights held by Goldman Sachs are 3.29%.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a notification regarding voting rights from the AFM (the Netherlands Authority For the Financial Markets). The notification details transactions by Goldman Sachs Group Inc., involving various types of shares, swaps, warrants, convertible bonds, and options, with both real and potential voting rights. The total capital interest and voting rights held by Goldman Sachs Group Inc. in QIAGEN N.V. is 3.29%.
QGEN|Qiagen NV|Price:41.435|Chg%:-0.375
This article provides a detailed analysis of Qiagen NV (QGEN) stock, highlighting its current market trends, real-time quotes, and related analysis. It covers key financial figures, insights into its growth potential and valuation, and analyst ratings, which currently lean towards "Buy." The company's strengths include high profit growth, while risks include institutional selling.
Amundi Has $190.50 Million Stake in Qiagen N.V. $QGEN
Amundi increased its stake in Qiagen N.V. by 12.4% in the first quarter, now holding 4.76 million shares valued at $190.5 million, representing 2.31% of the company.
PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG
This article announces that QIAGEN N.V. has published a voting rights notification in accordance with § 40 Abs. 1 WpHG, as informed by the AFM on July 29, 2026. The notification details various share and voting rights distributions related to Goldman Sachs Group Inc., The, resulting in a total capital interest and voting rights of 3.34% for Goldman Sachs. The transaction date was July 24, 2026, and the content is accessible on the AFM website.
QIAGEN Number of Employees 2026 | Employee Count & Headcount Data
QIAGEN NV (QGEN) has approximately 5,617 employees worldwide as of March 2026, marking a 6.6% decline from 2023. The company is actively hiring, with 272 job postings in 2026, though new postings per month have decreased. The workforce is primarily concentrated in the United States, Germany, and Poland, with an average salary of $73,467.
Veröffentlichung nach § 40 Abs. 1 WpHG
QIAGEN N.V. has released a voting rights notification as per § 40 Abs. 1 WpHG. The notification, disclosed by the AFM on July 29, 2026, details that Goldman Sachs Group Inc. has changed its holdings in QIAGEN N.V. The report specifies the distribution of shares and voting rights, both real and potential, across various Goldman Sachs entities.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM (the Netherlands Authority For the Financial Markets). The notification details various share and financial instrument holdings by Goldman Sachs Group Inc. and its affiliates, indicating both real and potential capital interest and voting rights in QIAGEN N.V. The total holding represents 3.40% of capital interest and voting rights, predominantly indirect.
Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. announced a voting rights notification as per Article 40, Section 1 of the WpHG. The notification, released by the AFM on July 29, 2026, details Goldman Sachs Group Inc.'s various holdings in QIAGEN N.V., including ordinary shares, swaps, warrants, and options, indicating both real and potential voting rights, totaling a capital interest and voting rights of 3.40%.
Qiagen NV (QGEN) Institutional Confidence
Qiagen NV (QGEN) has an institutional shareholding score of 7.00, placing it 80th out of 385 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 78.32%, a 4.59% increase quarter-over-quarter. ETHSX is the largest institutional shareholder, holding 980.90K shares, representing 0.43% of shares outstanding.
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
Analysts expect Qiagen (QGEN) to report a year-over-year decline in earnings and lower revenues for the quarter ended June 2026, with an expected earnings report date of August 5. The Zacks Earnings ESP for Qiagen is negative (-0.28%) and combined with a Zacks Rank of #4, suggests it's difficult to predict an earnings beat. Meanwhile, Rhythm Pharmaceuticals, Inc. (RYTM), an industry peer, shows a positive Earnings ESP and a Zacks Rank of #3, indicating a higher probability of beating estimates.
